biologic

M-M-R Ii

Measles, Mumps and Rubella Virus Vaccine Live

Loss of exclusivityFebruary 2035projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameM-M-R Ii
Active ingredientMeasles, Mumps and Rubella Virus Vaccine Live
Strength0.5ML
Dosage formFor Injection
RouteIntramuscular
ModalityBiologic
FDA approvalFebruary 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

M-M-R Ii patent cliff — loss of exclusivity February 2035 | CliffBio